Key Insights:
- INJ gained more than 23% in 24 hours as the SEC received 21Shares’ amended Injective ETF registration filing.
- The proposed 21Shares Injective ETF would trade on Nasdaq under TINJ and track INJ through the FTSE Injective Index.
- The amended filing allows discretionary INJ staking, while the SEC review continues and custody arrangements remain unresolved.
The price of INJ climbed approximately 18% over a 24-hour period on September 19 as Injective captured market attention through a pair of concurrent catalysts. Alongside these events, 21Shares submitted an updated Injective ETF filing following INJ’s native expansion onto Solana.
CoinMarketCap data placed Injective trading near $6.88. Because the token had already begun rallying in the wake of its September 17 Solana rollout, market observers could not attribute the price movement exclusively to the ETF amendment.
Injective Price Climbs as Trading Volume Expands
Over the span of 24 hours, Injective’s price shifted from about $5.98 up to $7.60. Trading charts demonstrated steady accumulation through the majority of the session, culminating in a sharper push past the $7.00 threshold. The INJ cryptocurrency eventually hovered near the upper boundary of its daily range after a brief touch near $7.70. Intraday momentum surged decisively once prices cleared $7.00, accompanied by sustained high volumes.
Market activity expanded in tandem with the rising valuation. CoinMarketCap statistics indicated a market capitalization of roughly $759.8 million, marking a 23.8% increase over the measured timeframe. Injective’s 24-hour trading volume reached approximately $281 million—a 194.4% surge—yielding a high volume-to-market-cap ratio of 36.61%.
Circulating supply metrics pointed to roughly 99.97 million INJ tokens actively circulating against a reported maximum supply cap of 100 million. This placed the fully diluted valuation close to $760.05 million, meaning the vast majority of the token supply was already circulating during the rally.
21Shares Updates Injective ETF Filing
On September 18, 21Shares submitted an updated S-1 registration statement for its proposed Injective ETF. This revision builds upon the initial filing originally presented on October 20, 2025. The vehicle is designed to offer direct market exposure to INJ via a traditional exchange-traded fund structure, though the regulatory filing itself does not grant authorization to launch public trading.
The revised proposal designates Nasdaq as the intended listing venue under the ticker symbol TINJ, utilizing the FTSE Injective Index as its underlying pricing benchmark. Furthermore, the updated framework grants 21Shares the discretion to stake a portion of the fund’s INJ assets, passing along staking yields to the product. Reports on the revision highlight a target staking allocation ranging between 40% and 60%, subject to ongoing liquidity requirements.
BNY Mellon is designated within the updated filing to act as administrator, transfer agent, and cash custodian. Meanwhile, the original S-1 identified 21Shares US LLC as the trust sponsor alongside its plans for direct token custody.
Solana Launch Broadens Access to INJ
The upward price action also coincided with the rollout of INJ as a native SPL token on the Solana network. This integration expanded accessibility across multiple Solana-centric trading platforms and decentralized finance (DeFi) protocols, including Jupiter, Raydium, Meteora, Pump.fun, and DFlow. CoinMarketCap highlighted the Solana debut alongside the ETF update during the identical trading window.
Although spot trading volumes spiked concurrently with both developments, prevailing market data do not differentiate purchase orders driven by the Solana deployment from those inspired by the ETF paperwork. The timing solely confirms that both milestones occurred simultaneously with the broader expansion of INJ’s price and trading activity.
INJ Price Prediction Targets $15.80 First
Projections from the latest INJ price forecast suggest the asset could advance toward $15.80, provided its established higher-low market structure remains intact. Analysts view $15.80 as the initial major resistance barrier, requiring the token to more than double from its $7.60 mark to breach that zone.
A successful break past $15.80 would shift attention to $33.20 as the subsequent technical hurdle. Beyond that, the forecast flags $47.16 as the next significant objective should the bullish trend persist.
This macro configuration mirrors a sequence of rising structural lows following prominent cycle highs achieved in both 2021 and 2024.
This article is for informational purposes only and does not constitute financial or investment advice. Cryptocurrency investments involve risk, and past performance does not guarantee future results. Readers should conduct their own research before making investment decisions.
Frequently Asked Questions
- Why did the INJ price rally?
The INJ price rallied amid a 24-hour surge driven by two primary developments: 21Shares updating its Injective ETF registration filing with the SEC and the token’s native launch on the Solana network. - What is the proposed ticker and exchange for the 21Shares Injective ETF?
The proposed 21Shares Injective ETF aims to list on Nasdaq under the ticker symbol TINJ and track the FTSE Injective Index. - Does the updated ETF filing allow staking?
Yes, the amended filing includes provisions for discretionary INJ staking, with reports indicating a target staking range between 40% and 60% depending on liquidity needs. - What are the current price targets for INJ according to forecasts?
Forecasters identify $15.80 as the first major resistance target, with subsequent potential checkpoints at $33.20 and $47.16 if the higher-low structure holds.